Literature DB >> 15507656

Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.

Nicole G Newcombe1, Leone G Beagley, Dale Christiansen, Bruce E Loveland, E Susanne Johansson, Ken W Beagley, Richard D Barry, Darren R Shafren.   

Abstract

Decay-accelerating factor (DAF) is involved in the cell membrane attachment of many human enteroviruses. Presently, further specific active roles of DAF in mediating productive cell infection and in the pathogenesis of natural enterovirus infection are poorly understood. In an attempt to more fully understand the role of DAF in lytic cell infection we examined the specific interactions of the prototype strain of coxsackievirus A21 (CVA21) with surface-expressed DAF. Investigations into discrete DAF-CVA21 interactions focused on viral binding; viral particle elution with respect to the parameters of time, temperature, and pH; and subsequent cell infection. Radiolabeled-virus binding assays revealed that peak elution of CVA21 from DAF occurred within 15 min of initial attachment and that the DAF-eluted virus increased in a linear fashion with respect to temperature and pH. CVA21 eluted from endogenous surface-expressed DAF was highly infectious, in contrast to CVA21 eluted from intercellular adhesion molecule 1 (ICAM-1), which retained little to no infectivity. Using an adenovirus transduction system, we demonstrate that CVA21 can remain infectious for up to 24 h after DAF binding and is capable of initiating a multicycle lytic infection upon delayed ICAM-1 surface expression. Taken together, the data suggest that a major role of DAF in cell infection by the prototype strain of CVA21 is to provide membrane concentration of infectious virions, effectively increasing viral interactions with endogenous or induced ICAM-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507656      PMCID: PMC525106          DOI: 10.1128/JVI.78.22.12677-12682.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Three-dimensional structure of poliovirus receptor bound to poliovirus.

Authors:  D M Belnap; B M McDermott; D J Filman; N Cheng; B L Trus; H J Zuccola; V R Racaniello; J M Hogle; A C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex.

Authors:  Yongning He; Feng Lin; Paul R Chipman; Carol M Bator; Timothy S Baker; Menachem Shoham; Richard J Kuhn; M Edward Medof; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

3.  Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection.

Authors:  Amanda D Stuart; Thomas A McKee; Pamela A Williams; Chris Harley; Shuo Shen; David I Stuart; T David K Brown; Susan M Lea
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatibility complex class I molecules which mediate virus internalization.

Authors:  Kathy Triantafilou; Didier Fradelizi; Keith Wilson; Martha Triantafilou
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55.

Authors:  S M Lea; R M Powell; T McKee; D J Evans; D Brown; D I Stuart; P A van der Merwe
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

6.  Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.

Authors:  T A Martino; M Petric; M Brown; K Aitken; C J Gauntt; C D Richardson; L H Chow; P P Liu
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

7.  Interaction of coxsackievirus A21 with its cellular receptor, ICAM-1.

Authors:  C Xiao; C M Bator; V D Bowman; E Rieder; Y He; B Hébert; J Bella; T S Baker; E Wimmer; R J Kuhn; M G Rossmann
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription.

Authors:  A Papi; S L Johnston
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

9.  Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.

Authors:  T M Karnauchow; S Dawe; D M Lublin; K Dimock
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts.

Authors:  Amanda D Stuart; Hannah E Eustace; Thomas A McKee; T D K Brown
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  5 in total

1.  Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA.

Authors:  Noura B Elsedawy; Rebecca A Nace; Stephen J Russell; Autumn J Schulze
Journal:  Mol Ther Oncolytics       Date:  2020-05-19       Impact factor: 7.200

2.  Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.

Authors:  Ian G Goodfellow; David J Evans; Anna M Blom; Dave Kerrigan; J Scott Miners; B Paul Morgan; O Brad Spiller
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.

Authors:  E Susanne Johansson; Li Xing; R Holland Cheng; Darren R Shafren
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 4.  Applications of coxsackievirus A21 in oncology.

Authors:  Stephen Bradley; Adam D Jakes; Kevin Harrington; Hardev Pandha; Alan Melcher; Fiona Errington-Mais
Journal:  Oncolytic Virother       Date:  2014-04-10

Review 5.  Viral Vector-Based Melanoma Gene Therapy.

Authors:  Altijana Hromic-Jahjefendic; Kenneth Lundstrom
Journal:  Biomedicines       Date:  2020-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.